NCT05319314Phase 1, phase 2Recruiting

LYL273 for Patients With Relapsed or Refractory mCRC

Study sponsor: Lyell Immunopharma, Inc. · LYEL

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06Estimated
Enrollment · participants155Estimated
Source updated2026-10-30Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.